bcr_followup_barcode	additional_pharmaceutical_therapy	additional_radiation_therapy	additional_surgery_locoregional_procedure	bcr_followup_uuid	day_of_form_completion	days_to_additional_surgery_metastatic_procedure	days_to_death	days_to_last_followup	days_to_new_tumor_event_after_initial_treatment	followup_case_report_form_submission_reason	her2_neu_and_centromere_17_copy_number_metastatic_breast_carcinoma_analysis_input_total_number_count	her2_neu_metastatic_breast_carcinoma_copy_analysis_input_total_number	metastatic_breast_carcinoma_erbb2_immunohistochemistry_level_result	metastatic_breast_carcinoma_estrogen_receptor_detection_method_text	metastatic_breast_carcinoma_estrogen_receptor_level_cell_percent_category	metastatic_breast_carcinoma_estrogen_receptor_status	metastatic_breast_carcinoma_fluorescence_in_situ_hybridization_diagnostic_proc_centromere_17_signal_result_range	metastatic_breast_carcinoma_her2_erbb_method_calculation_method_text	metastatic_breast_carcinoma_her2_erbb_pos_finding_cell_percent_category	metastatic_breast_carcinoma_her2_erbb_pos_finding_fluorescence_in_situ_hybridization_calculation_method_text	metastatic_breast_carcinoma_her2_neu_chromosone_17_signal_ratio_value	metastatic_breast_carcinoma_immunohistochemistry_er_pos_cell_score	metastatic_breast_carcinoma_immunohistochemistry_er_positive_finding_scale_type	metastatic_breast_carcinoma_immunohistochemistry_pr_pos_cell_score	metastatic_breast_carcinoma_immunohistochemistry_progesterone_receptor_positive_finding_scale_type	metastatic_breast_carcinoma_lab_proc_her2_neu_immunohistochemistry_receptor_status	metastatic_breast_carcinoma_lab_proc_her2_neu_in_situ_hybridization_outcome_type	metastatic_breast_carcinoma_pos_finding_her2_erbb2_other_measure_scale_text	metastatic_breast_carcinoma_pos_finding_other_scale_measurement_text	metastatic_breast_carcinoma_pos_finding_progesterone_receptor_other_measure_scale_text	metastatic_breast_carcinoma_progesterone_receptor_detection_method_text	metastatic_breast_carcinoma_progesterone_receptor_level_cell_percent_category	metastatic_breast_carcinoma_progesterone_receptor_status	month_of_form_completion	new_neoplasm_event_occurrence_anatomic_site	new_neoplasm_event_type	new_tumor_event_after_initial_treatment	person_neoplasm_cancer_status	pos_finding_metastatic_breast_carcinoma_estrogen_receptor_other_measuremenet_scale_text	radiation_therapy	targeted_molecular_therapy	vital_status	year_of_form_completion
TCGA-A2-A0CX-F13721	[Not Available]	[Not Available]	[Not Available]	2A0B12FB-64F9-49DF-ACC6-22D1110B827C	10	[Not Available]	[Not Available]	1728	[Not Available]	Scheduled Follow-up Submission	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	6	[Not Available]	[Not Available]	NO	TUMOR FREE	[Not Available]	YES	YES	LIVING	2011
TCGA-A2-A0D0-F13729	[Not Available]	[Not Available]	[Not Available]	4F4DEDB3-173C-4B24-B46B-D1DDCB67A318	9	[Not Available]	[Not Available]	643	[Not Available]	Scheduled Follow-up Submission	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	6	[Not Available]	[Not Available]	NO	TUMOR FREE	[Not Available]	NO	YES	LIVING	2011
TCGA-A2-A0D4-F13726	[Not Available]	[Not Available]	[Not Available]	F768A36A-1B8C-45BE-9D50-F05E55C3BF24	10	[Not Available]	[Not Available]	767	[Not Available]	Scheduled Follow-up Submission	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	6	[Not Available]	[Not Available]	NO	TUMOR FREE	[Not Available]	YES	YES	LIVING	2011
TCGA-AO-A03P-F15452	[Not Available]	[Not Available]	NO	46278B90-E76B-4B39-B3C0-42D6AC1CF690	22	[Not Available]	2911	[Not Available]	1922	Scheduled Follow-up Submission	40	4.0	2+	[Not Available]	90-99%	Positive	2.4	3 Point Scale	20-29%	RATIO >2.2	1.7	4+	4 Point Scale	2+	4 Point Scale	Equivocal	Negative	[Not Available]	[Not Available]	[Not Available]	[Not Available]	80-89%	Positive	8	Liver	Distant Metastasis	YES	WITH TUMOR	[Not Available]	YES	NO	DECEASED	2011
TCGA-BH-A0AY-F15456	[Not Available]	[Not Available]	[Not Available]	A54FAA28-CE61-4E7A-A5C4-2CC9FFE880CA	3	[Not Available]	[Not Available]	777	[Not Available]	Scheduled Follow-up Submission	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	11	[Not Available]	[Not Available]	NO	TUMOR FREE	[Not Available]	NO	YES	LIVING	2010
TCGA-BH-A0B4-F15435	[Not Available]	[Not Available]	[Not Available]	AE2D2C86-0F6F-4CD9-9D52-361A471B6676	4	[Not Available]	[Not Available]	1191	[Not Available]	Scheduled Follow-up Submission	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	[Not Available]	11	[Not Available]	[Not Available]	NO	TUMOR FREE	[Not Available]	YES	YES	LIVING	2010
